XML 89 R64.htm IDEA: XBRL DOCUMENT
v3.25.4

COMMITMENTS AND CONTINGENCIES (Details) $ in Thousands |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | ---
Nov. 28, 2025 USD ($) | Dec. 22, 2022 USD ($) quarterly_payment | Feb. 10, 2021 | Apr. 17, 2019 | Dec. 31, 2025 USD ($) | Sep. 30, 2025 USD ($) | Dec. 31, 2024 USD ($) | Jun. 30, 2021 USD ($) | Mar. 31, 2020 | Jun. 30, 2021 USD ($) | Dec. 31, 2025 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($)
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Change in excess firm purchase commitment liability |  |  |  |  |  |  |  |  |  |  | $ 0 | $ 2,100 | $ 1,500
Research and development |  |  |  |  |  |  |  |  |  |  | 62,359 | 37,652 | 63,079
Contract cost incurred in research and development activities |  |  |  |  |  |  |  |  |  |  | 82,600 |  |
Charge for purchase of IPR&D asset |  |  |  |  |  |  |  |  |  |  | 12,807 | 0 | 0
Siegfried Evionnaz SA |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Cost of purchased minimum quantity product |  |  |  |  | $ 800 |  |  |  |  |  | 800 |  |
Excess firm purchase commitment charge |  |  |  |  |  |  |  |  |  |  | 800 | 3,600 |
Patheon | Vafseo Drug Product |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Purchase commitment, option for non-auto renewal, prior written notice period (in months) |  |  |  |  |  |  |  |  | 18 months |  |  |  |
Minimum purchase commitment |  |  |  |  | 1,100 |  |  |  |  |  | 1,100 |  |
STA Pharmaceutical Hong Kong Limited |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Excess firm purchase commitment charge |  |  |  |  |  |  |  |  |  |  | 69,200 |  |
WuXi STA |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Excess firm purchase commitment charge |  |  |  |  |  |  |  |  |  |  | 1,800 |  |
Purchase commitment, option to extend, prior notice period (in months) |  |  | 18 months |  |  |  |  |  |  |  |  |  |
Long-term purchase commitment, option to terminate, prior notice period (at least) |  |  | 180 days |  |  |  |  |  |  |  |  |  |
BioVectra Inc |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Long-term purchase commitment, termination amount payable |  | $ 32,500 |  |  |  |  |  |  |  |  |  |  |
Long-term purchase commitment, upfront payment termination amount |  | $ 17,500 |  |  |  |  |  |  |  |  |  |  |
Long-term purchase commitment, termination amount payable after upfront payment, number of quarterly periods | quarterly_payment |  | 6 |  |  |  |  |  |  |  |  |  |  |
Long-term purchase commitment, termination amount payable after upfront payment, per quarter |  | $ 2,500 |  |  |  |  |  |  |  |  |  |  |
Long-term purchase commitment, termination amount payable after upfront payment |  | $ 15,000 |  |  |  |  |  |  |  |  |  |  |
Long-term purchase commitment, imputed interest on termination amount payable |  | 17.00% |  |  |  |  |  |  |  |  |  |  |
Long-term purchase commitment, upfront termination amount classified as cost of goods sold |  | $ 11,200 |  |  |  |  |  |  |  |  |  |  |
Amortization discount |  |  |  |  |  |  |  |  |  |  | 300 | 1,600 | 1,900
Panion & BF Biotech, Inc | License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
License agreement, notice period for termination |  |  |  | 90 days |  |  |  |  |  |  |  |  |
Royalty payments |  |  |  |  |  |  |  |  |  |  | $ 11,300 | 9,100 | $ 10,000
Cyclerion | License Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Expiration period beginning with first commercial sale (in years) |  |  |  |  |  |  |  |  |  |  | 10 years |  |
Termination period, prior written notice (in days) |  |  |  |  |  |  |  |  |  |  | 180 days |  |
Cyclerion | License Agreement | Acquired Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments |  |  |  |  |  |  |  |  |  | $ 3,000 |  |  |
Cyclerion | License Agreement | Acquired Licenses | Research and development |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments |  |  |  |  |  |  |  | $ 3,000 |  |  |  |  |
Cyclerion | Cyclerion Amendment | Acquired Licenses |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments |  |  |  |  |  | $ 500 | $ 1,250 |  |  |  |  |  |
Specified development and regulatory milestone payments, contingent on a product-by-product basis |  |  |  |  |  |  |  |  |  |  | $ 197,500 |  |
Research and development |  |  |  |  | $ 1,000 |  |  |  |  |  |  |  |
Cyclerion | Cyclerion Amendment | Acquired Licenses | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Tiered royalties (as percent) |  |  |  |  | 20.00% |  |  |  |  |  | 20.00% |  |
Cyclerion | Cyclerion Amendment | Acquired Licenses | Research and development |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments |  |  |  |  |  |  |  |  |  |  |  | 1,250 |
Contingent consideration |  |  |  |  |  |  |  |  |  |  |  | $ 500 |
Cyclerion | Cyclerion Amendment | Acquired Licenses | Accrued Liabilities |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent consideration |  |  |  |  |  |  |  |  |  |  | $ 1,000 |  |
Q32 | Q32 Asset Purchase Agreement |  |  |  |  |  |  |  |  |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payments | $ 12,800 |  |  |  |  |  |  |  |  |  |  |  |
Specified development and regulatory milestone payments, contingent on a product-by-product basis | 94,500 |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | 7,000 |  |  |  |  |  |  |  |  |  |  |  |
Additional upfront payment | $ 3,000 |  |  |  |  |  |  |  |  |  | 3,000 |  |
Additional payment term | 6 months |  |  |  |  |  |  |  |  |  |  |  |
Development milestone payment | $ 2,000 |  |  |  |  |  |  |  |  |  | 2,000 |  |
Commercial milestone payment | 487,500 |  |  |  |  |  |  |  |  |  |  |  |
Asset acquisition, consideration transferred, transaction cost | $ 800 |  |  |  |  |  |  |  |  |  |  |  |
Charge for purchase of IPR&D asset |  |  |  |  |  |  |  |  |  |  | $ 12,800 |  |

X
- Definition Asset Acquisition, Additional Payment Term + References No definition available. + Details
Name: | akba_AssetAcquisitionAdditionalPaymentTerm
Namespace Prefix: | akba_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Asset Acquisition, Additional Upfront Payment + References No definition available. + Details
Name: | akba_AssetAcquisitionAdditionalUpfrontPayment
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition "Asset Acquisition, Consideration Transferred, Contingent Consideration, Commercial Milestone Payment + References No definition available. + Details
Name: | akba_AssetAcquisitionConsiderationTransferredContingentConsiderationCommercialMilestonePayment
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Consideration Transferred, Contingent Consideration, Development and Regulatory Milestone Payments + References No definition available. + Details
Name: | akba_AssetAcquisitionConsiderationTransferredContingentConsiderationDevelopmentAndRegulatoryMilestonePayments
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Development Milestone Payment + References No definition available. + Details
Name: | akba_AssetAcquisitionDevelopmentMilestonePayment
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Asset Acquisition, Upfront Payment + References No definition available. + Details
Name: | akba_AssetAcquisitionUpfrontPayment
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cost of purchased minimum quantity product. + References No definition available. + Details
Name: | akba_CostOfPurchasedMinimumQuantityProduct
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Expiration Period Beginning with First Commercial Sale + References No definition available. + Details
Name: | akba_ExpirationPeriodBeginningWithFirstCommercialSale
Namespace Prefix: | akba_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition License agreement, termination, notice period. + References No definition available. + Details
Name: | akba_LicenseAgreementTerminationNoticePeriod
Namespace Prefix: | akba_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Long-Term Purchase Commitment, Change In Excess Liability, Cost Of Goods Sold + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentChangeInExcessLiabilityCostOfGoodsSold
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Long-Term Purchase Commitment, Discount Amortization + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentDiscountAmortization
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Long-Term Purchase Commitment, Option To Extend, Prior Notice Period + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentOptionToExtendPriorNoticePeriod
Namespace Prefix: | akba_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Long-Term Purchase Commitment, Option To Terminate, Prior Notice Period + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentOptionToTerminatePriorNoticePeriod
Namespace Prefix: | akba_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Long-Term Purchase Commitment, Termination Amount Payable + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentTerminationAmountPayable
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Long-Term Purchase Commitment, Termination Amount Payable, After Upfront Payment + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentTerminationAmountPayableAfterUpfrontPayment
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Long-Term Purchase Commitment, Termination Amount Payable, After Upfront Payment, Number Of Quarterly Payments + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentTerminationAmountPayableAfterUpfrontPaymentNumberOfQuarterlyPayments
Namespace Prefix: | akba_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Long-Term Purchase Commitment, Termination Amount Payable, After Upfront Payment, Per Quarter + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentTerminationAmountPayableAfterUpfrontPaymentPerQuarter
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Long-Term Purchase Commitment, Termination Amount Payable, Imputed Interest + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentTerminationAmountPayableImputedInterest
Namespace Prefix: | akba_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Long-Term Purchase Commitment, Upfront Payment Termination Amount + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentUpfrontPaymentTerminationAmount
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Long-Term Purchase Commitment, Upfront Termination Amount, Cost Of Goods Sold + References No definition available. + Details
Name: | akba_LongTermPurchaseCommitmentUpfrontTerminationAmountCostOfGoodsSold
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Purchase Commitment, Option For Non-Auto Renewal, Prior Written Notice Period + References No definition available. + Details
Name: | akba_PurchaseCommitmentOptionForNonAutoRenewalPriorWrittenNoticePeriod
Namespace Prefix: | akba_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue, Remaining Performance Obligation, Variable Consideration, Royalty Percentage + References No definition available. + Details
Name: | akba_RevenueRemainingPerformanceObligationVariableConsiderationRoyaltyPercentage
Namespace Prefix: | akba_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Royalty payments due. + References No definition available. + Details
Name: | akba_RoyaltyPaymentsDue
Namespace Prefix: | akba_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Termination Period, Prior Written Notice + References No definition available. + Details
Name: | akba_TerminationPeriodPriorWrittenNotice
Namespace Prefix: | akba_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of contingent consideration recognized as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction cost incurred as part of consideration transferred in asset acquisition. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479908/805-50-55-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2 + Details
Name: | us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The minimum amount the entity agreed to spend under the long-term purchase commitment. + References No definition available. + Details
Name: | us-gaap_LongTermPurchaseCommitmentAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum amount to be expended to satisfy the terms of arrangements in which the entity has agreed to expend funds to procure goods or services, excluding long-term purchase commitments or unconditional purchase obligations. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_PurchaseCommitmentRemainingMinimumAmountCommitted
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of costs incurred under a research and development arrangement accounted for as a contract to perform research and development for others. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483041/730-20-50-1 + Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of writeoff for research and development asset acquired in transaction other than business combination or from joint venture formation or both. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21 + Details
Name: | us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=akba_SiegfriedEvionnazSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=akba_PatheonMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=akba_VafseoDrugProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=akba_STAPharmaceuticalHongKongLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=akba_WuXiSTAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=akba_BioVectraIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=akba_PanionBFBiotechIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=akba_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=akba_CyclerionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=akba_AcquiredLicensesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=akba_CyclerionAmendmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_AccruedLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=akba_Q32Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AssetAcquisitionAxis=akba_Q32AssetPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |